Changing The Subject (Part 1): Stop Trying To “Win” The Drug Pricing Debate
When it comes to pricing, it is worth remembering that the interests of buyers and sellers can never be truly aligned. So rather than trying to “win” the drug pricing debate, the pharmaceutical industry may be better served by steering it into new areas. We plan to propose some big ideas that might work in that direction.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?